Literature DB >> 8358631

Blockade of morphine-induced analgesia and tolerance in mice by MK-801.

K Lutfy1, D E Hurlbut, E Weber.   

Abstract

The effect of MK-801 on morphine-induced analgesia, tolerance and opioid binding sites was examined in mice. In analgesia studies, mice received either naloxone or MK-801. Controls were injected with saline. Mice were then injected with morphine 10 or 30 min following naloxone or MK-801, respectively, and tested for analgesia (tail flick assay) 45 min later. Pretreatment with naloxone or MK-801 blocked morphine-induced analgesia. In tolerance studies, mice were pretreated with either saline or MK-801. Thirty minutes later, mice were injected with either saline or morphine (acutely or chronically) and tested for analgesia 24 h later. Pretreatment with MK-801 partially or completely blocked the development of acute and chronic tolerance, respectively. In binding studies, MK-801 displaced [3H]naloxone poorly compared to naloxone or morphine. Together, these data suggest a role for NMDA receptors in morphine-induced analgesia and tolerance. The poor inhibition of the [3H]naloxone binding sites by MK-801 supports the possibility that MK-801 might not act directly on the opioid receptors, but rather, inhibits morphine-induced analgesia and tolerance by some other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358631     DOI: 10.1016/0006-8993(93)90195-s

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

2.  Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.

Authors:  P Popik; E Kozela; A Pilc
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Effects of competitive and noncompetitive antagonists of the N-methyl-D-aspartate receptor on the analgesic action of delta 1- and delta 2-opioid receptor agonists in mice.

Authors:  H N Bharagava; G M Zhao
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

4.  Orphanin FQ/nociceptin attenuates the development of morphine tolerance in rats.

Authors:  K Lutfy; S M Hossain; I Khaliq; N T Maidment
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

5.  The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice.

Authors:  E Del Pozo; M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

6.  Blockade of NMDA receptors prevents analgesic tolerance to repeated transcutaneous electrical nerve stimulation (TENS) in rats.

Authors:  Priyanka M Hingne; Kathleen A Sluka
Journal:  J Pain       Date:  2007-12-03       Impact factor: 5.820

7.  Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine.

Authors:  Yukun Chen; Marianne Evola; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-04       Impact factor: 4.530

8.  The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats.

Authors:  I Nylander; M Vlaskovska; L Terenius
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  Effects of post-ethanol administration of NMDA and non-NMDA receptor antagonists on the development of ethanol tolerance in C57B1 mice.

Authors:  M Karcz-Kubicha; S Liljequist
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

Review 10.  Synthesis of the Mechanisms of Opioid Tolerance: Do We Still Say NO?

Authors:  Laura J Gledhill; Anna-Marie Babey
Journal:  Cell Mol Neurobiol       Date:  2021-03-11       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.